About Us

PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Our lead programs are focused on Autism Spectrum Disorder (ASD). There are no FDA-approved treatments for the core symptoms of ASD. As the publicly traded US company focused exclusively on Autism, we are on a promising path to change that.


Howard Weisman

Chairman and CEO

Stephen D. Sheldon

Chief Operating Officer / CFO

David Hough M.D.

Chief Medical Officer

Buzz Woods

Corporate Communications

Board of Directors

Howard Weisman

Zach Rome

Dr. John F. Coelho

Karen LaRochelle

Charles J. Casamento

Advisory Board


We are continuing to pursue opportunities to license or acquire additional late-stage assets and are dedicated to collaborating with companies, academia, patient advocacy groups, and other industry stakeholders worldwide. If you are interested in a partnership with PaxMedica, please contact us at info@paxmedica.com.

For People with Autism and Their Families

If you are interested in following our progress or learning more about our clinical trials, please complete the contact form.

PaxMedica is a proud partner of:

Supporting translational research that will lead to the development of FDA-approved treatments and an improved standard of care for co-morbidities in individuals with autism.